MeiraGTx Holdings plc (MGTX)
MGTX Stock Price Chart
Explore MeiraGTx Holdings plc interactive price chart. Choose custom timeframes to analyze MGTX price movements and trends.
MGTX Company Profile
Discover essential business fundamentals and corporate details for MeiraGTx Holdings plc (MGTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Jun 2018
Employees
375.00
Website
https://www.meiragtx.comCEO
Alexandria Forbes
Description
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
MGTX Financial Timeline
Browse a chronological timeline of MeiraGTx Holdings plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.51, while revenue estimate is $7.71M.
Earnings released on 14 Aug 2025
EPS came in at -$0.48 surpassing the estimated -$0.52 by +7.69%, while revenue for the quarter reached $3.69M , missing expectations by -43.08%.
Earnings released on 13 May 2025
EPS came in at -$0.51 falling short of the estimated -$0.38 by -34.21%, while revenue for the quarter reached $1.93M , missing expectations by -56.62%.
Earnings released on 13 Mar 2025
EPS came in at -$0.50 falling short of the estimated -$0.48 by -4.17%, while revenue for the quarter reached $21.39M , beating expectations by +1.33K%.
Earnings released on 13 Nov 2024
EPS came in at -$0.54 falling short of the estimated -$0.47 by -14.89%, while revenue for the quarter reached $10.91M , beating expectations by +573.46%.
Earnings released on 12 Aug 2024
EPS came in at -$0.76 falling short of the estimated -$0.31 by -145.16%, while revenue for the quarter reached $282.00K , missing expectations by -97.09%.
Earnings released on 9 May 2024
EPS came in at -$0.77 falling short of the estimated -$0.32 by -140.63%, while revenue for the quarter reached $697.00K , missing expectations by -92.81%.
Earnings released on 14 Mar 2024
EPS came in at -$0.47 falling short of the estimated -$0.46 by -2.17%, while revenue for the quarter reached $2.04M , missing expectations by -68.90%.
Earnings released on 14 Nov 2023
EPS came in at -$0.74 falling short of the estimated -$0.63 by -17.46%, while revenue for the quarter reached $5.10M , beating expectations by +45.80%.
Earnings released on 10 Aug 2023
EPS came in at -$0.53 surpassing the estimated -$0.59 by +10.17%, while revenue for the quarter reached $3.54M , missing expectations by -15.11%.
Earnings released on 11 May 2023
EPS came in at -$0.62 surpassing the estimated -$0.65 by +4.62%, while revenue for the quarter reached $3.33M , missing expectations by -31.40%.
Earnings released on 14 Mar 2023
EPS came in at -$0.58 falling short of the estimated $0.49 by -218.37%, while revenue for the quarter reached -$5.29M , missing expectations by -159.28%.
Earnings released on 10 Nov 2022
EPS came in at -$0.83 falling short of the estimated -$0.50 by -66.00%, while revenue for the quarter reached $4.82M , missing expectations by -55.83%.
Earnings released on 11 Aug 2022
EPS came in at -$0.76 falling short of the estimated -$0.58 by -31.03%, while revenue for the quarter reached $10.76M , beating expectations by +53.82%.
Earnings released on 12 May 2022
EPS came in at -$0.70 falling short of the estimated -$0.49 by -42.86%, while revenue for the quarter reached $5.63M , missing expectations by -3.15%.
Earnings released on 10 Mar 2022
EPS came in at -$0.22 surpassing the estimated -$0.49 by +55.10%, while revenue for the quarter reached $21.04M , beating expectations by +415.47%.
Earnings released on 10 Nov 2021
EPS came in at -$0.59 falling short of the estimated -$0.52 by -13.46%, while revenue for the quarter reached $6.95M , beating expectations by +189.46%.
Earnings released on 11 Aug 2021
EPS came in at -$0.46 surpassing the estimated -$0.53 by +13.21%, while revenue for the quarter reached $5.12M , beating expectations by +115.86%.
Earnings released on 11 May 2021
EPS came in at -$0.54 falling short of the estimated -$0.43 by -25.58%, while revenue for the quarter reached $4.60M , beating expectations by +40.00%.
Earnings released on 11 Mar 2021
EPS came in at -$0.25 surpassing the estimated -$0.38 by +34.21%, while revenue for the quarter reached $3.79M .
Earnings released on 5 Nov 2020
EPS came in at -$0.17 surpassing the estimated -$0.77 by +77.92%, while revenue for the quarter reached $5.09M , missing expectations by -36.77%.
MGTX Stock Performance
Access detailed MGTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.